Denosumab: 16 Real Stories

16 stories match denosumab. 10 of them mention radiation.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA EGFR-mutated lung adenocarcinoma: stable disease on first-line osimertinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; baseline EGFR exon 20 T790M mutation; ALK IHC negative; PD-L1 TPS 30%; TTF-1-positive

Metastatic Site: pleura; malignant pleural-pericardial adhesions

As of April 2026, she had stable disease for more than 9 months on first-line osimertinib, with no progressive disease, no recurrent pleural effusion, ECOG improvement from 2 to 0, and no treatment-related adverse events.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV METex14 lung adenocarcinoma: responding well to capmatinib and SBRT

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; PD-L1 >80%. EGFR/RAS/MEK wild type; lung-origin markers present.

Metastatic Site: brain; bone (thoracic/lumbar vertebrae, right iliac…

At 24 months after diagnosis, he was alive, asymptomatic, and continuing capmatinib with no evidence of progression and excellent tolerance.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Male breast cancer history complicated by suspected bone disease and later IgG-kappa multiple myeloma

Patient Info: Anonymized, Male, 60s | Stage I

Biomarkers: Breast cancer was ER/PR-positive and HER2-negative by FISH. Later workup showed IgG-kappa multiple myeloma with IgH rearrangement.

The patient achieved very good partial response after KBD and completed autologous hematopoietic stem cell transplantation with engraftment, but later died of a novel coronavirus infection.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic rectal cancer: total scapulectomy improves pain and function

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: CEA 418 ng/mL preoperatively; 10.3 ng/mL postoperatively; 7.2 ng/mL at 7 months; 11.1 ng/mL at about 5 months postoperatively; 6.4 ng/mL at 8 months

Metastatic Site: liver, right acromion/scapula, left adrenal gland

The patient had meaningful pain relief and functional recovery after total scapulectomy, but later developed liver and left adrenal progression and remained on palliative chemotherapy with a positive response.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Breast AdenocarcinomaBreast Cancer

Metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-positive breast cancer. Jaw workup focused on osteonecrosis

Metastatic Site: bone / osseous metastasis

The case focused on metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw after antiresorptive therapy; dental pain improved transiently after oral-surgery interventions, but systemic cancer response was not described.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage I Pleomorphic Lung Cancer Recurring With Bone Metastasis Within Five Months

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 high; no detected driver mutation

Metastatic Site: bone

PET-CT in December 2024 showed a partial response. As of February 2025, he remained on sintilimab and bevacizumab maintenance with about 9 months of progression-free survival after recurrence treatment.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colorectal Cancer With Severe Hypocalcemia After Denosumab

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: MLH1, PMS2, MSH2 and MSH6 retained; DPYD wild type

Metastatic Site: bone, liver

Bone imaging in November 2023 showed progression with more extensive skeletal involvement while he remained under care for metastatic colorectal cancer.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage 4 lobular breast cancer: bone therapy switch to denosumab

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Not reported for breast cancer; CRP 21 mg/dL and ESR 27 mm/hr were elevated during orbital inflammation workup

Metastatic Site: bone

As of April 2024, zoledronate-associated ocular inflammation resolved within 2.5 weeks, vision returned to 20/20 after about 3 weeks, and bone-support treatment was changed to denosumab; breast-cancer response was not reported.

PubMed Central
OutcomeCare Ongoing
Amy, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage IV MET Lung Squamous Cell Carcinoma: Amy's Patient Story

Patient Info: Amy, Female | Stage IV

Biomarkers: MET amplification

Metastatic Site: Bone/femur; lymph nodes; shoulder; adrenal glands;…

As of July 2022, Amy had a rapid and strong response to Crizotinib after MET amplification was found, with pain and lumps improving within about 2 weeks after Keytruda had failed.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic ER-positive breast cancer complicated by osteonecrosis of the jaw

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive.

Metastatic Site: bone (sternum, spine, pelvis, and proximal femur)

After progressive metastatic bone disease and severe medication-related osteonecrosis of the jaw, she entered end-of-life care and died three weeks after discharge to a nursing home.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Lobular Breast Cancer Spreading to an Eye Muscle

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Hormone receptor-positive; HER2-negative; E-cadherin-negative; CK7-positive

Metastatic Site: bones|left superior oblique eye muscle

The eye-muscle metastasis entered complete local remission, while bone disease was stable after 6 months of weekly paclitaxel and denosumab.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Breast cancer recurrence presenting with numb chin syndrome

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: sternum, left mandibular foramen

She was discharged ambulatory without lower-limb pain, although left mandibular numbness persisted, with monthly oncology follow-up planned.

PubMed Central
OutcomeLiving With Cancer